SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Fei Xue, Haijun Ma, Catherine Stehman-Breen, Christine Haller, Leonid Katz, Rachel B. Wagman, Cathy W. Critchlow, Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis, Pharmacoepidemiology and Drug Safety, 2013, 22, 10
  2. 2
    Seoyoung C. Kim, Craig Newcomb, David Margolis, Jason Roy, Sean Hennessy, Severe Cutaneous Reactions Requiring Hospitalization in Allopurinol Initiators: A Population-Based Cohort Study, Arthritis Care & Research, 2013, 65, 4
  3. 3
    Robert A. Schwartz, Patrick H. McDonough, Brian W. Lee, Toxic epidermal necrolysis, Journal of the American Academy of Dermatology, 2013, 69, 2, 173.e1

    CrossRef

  4. You have free access to this content4
    Gary Schneider, Sumesh Kachroo, Natalie Jones, Sheila Crean, Philip Rotella, Ruzan Avetisyan, Matthew W. Reynolds, A systematic review of validated methods for identifying erythema multiforme major/minor/not otherwise specified, Stevens–Johnson Syndrome, or toxic epidermal necrolysis using administrative and claims data, Pharmacoepidemiology and Drug Safety, 2012, 21,
  5. 5
    Vincent Lo Re, Kevin Haynes, Eileen E. Ming, Jennifer Wood Ives, Laura N. Horne, Kimberly Fortier, Dena M. Carbonari, Sean Hennessy, Serena Cardillo, Peter P. Reese, K. Rajender Reddy, David Margolis, Andrea Apter, Stephen E. Kimmel, Jason Roy, Cristin P. Freeman, Hanieh Razzaghi, Crystal N. Holick, Daina B. Esposito, Tjeerd-Pieter Van Staa, Harshvinder Bhullar, Brian L. Strom, Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies, Pharmacoepidemiology and Drug Safety, 2012, 21, 11
  6. 6
    Yasuo Takahashi, Yayoi Nishida, Satoshi Asai, Utilization of health care databases for pharmacoepidemiology, European Journal of Clinical Pharmacology, 2012, 68, 2, 123

    CrossRef

  7. 7
    Debra F Eisenberg, Gregory W Daniel, Judith K Jones, Earl L Goehring, Peter M Wahl, Peter Winters, Jay Levin, Rhonda L Bohn, Validation of a claims-based diagnostic code for Stevens–Johnson syndrome in a commercially insured population, Pharmacoepidemiology and Drug Safety, 2012, 21, 7
  8. 8
    Emily Cox, Bradley C. Martin, Tjeerd Van Staa, Edeltraut Garbe, Uwe Siebert, Michael L. Johnson, Good Research Practices for Comparative Effectiveness Research: Approaches to Mitigate Bias and Confounding in the Design of Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report—Part II, Value in Health, 2009, 12, 8
  9. 9
    F. Hoffmann, F. Andersohn, K Giersiepen, E. Scharnetzky, Edeltraut Garbe, Validierung von Sekundärdaten, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2008, 51, 10, 1118

    CrossRef

  10. 10
    Brian L. Strom, Methodologic Challenges to Studying Patient Safety and Comparative Effectiveness, Medical Care, 2007, 45, Suppl 2, S13

    CrossRef

  11. 11
    Samy Suissa, Edeltraut Garbe, Primer: administrative health databases in observational studies of drug effects—advantages and disadvantages, Nature Clinical Practice Rheumatology, 2007, 3, 12, 725

    CrossRef

  12. 12
    M.-S. Lin, Y.-S. Dai, R.-F. Pwu, Y.-H. Chen, N.-C. Chang, Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study, Internal Medicine Journal, 2005, 35, 3
  13. 13
    Faten N Aberra, James D Lewis, David Hass, John L Rombeau, Benjamin Osborne, Gary R Lichtenstein, Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients, Gastroenterology, 2003, 125, 2, 320

    CrossRef

  14. 14
    David J. Margolisa,b,c, Warren Bilkerb,c, Jill Santannab,c, Mona Baumgartenc,d, Venous leg ulcer: Incidence and prevalence in the elderly, Journal of the American Academy of Dermatology, 2002, 46, 3, 381

    CrossRef

  15. 15
    Brian L. Strom, Data validity issues in using claims data, Pharmacoepidemiology and Drug Safety, 2001, 10, 5
  16. 16
    Charles R Woods, Impact of different definitions on estimates of accuracy of the diagnosis data in a clinical database, Journal of Clinical Epidemiology, 2001, 54, 8, 782

    CrossRef

  17. 17
    Jonathan Kantor, David J Margolis, The accuracy of using a wound care specialty clinic database to study diabetic neuropathic foot ulcers, Wound Repair and Regeneration, 2000, 8, 3
  18. 18
    Hong Sang Lau, Christa Florax, Arijan J. Porsius, Anthonius De Boer, The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards, British Journal of Clinical Pharmacology, 2000, 49, 6
  19. 19
    Stephen E Kimmel, Martin G Keane, Jack L Crary, Jane Jones, Judith L Kinman, Jeanne Beare, Mary Sammel, Martin St. John Sutton, Brian L Strom, Detailed examination of fenfluramine-phentermine users with valve abnormalities identified in Fargo, North Dakota, The American Journal of Cardiology, 1999, 84, 3, 304

    CrossRef

  20. 20
    Suzy I. Sjahid, Paul D. Van Der Linden, Bruno H. Ch. Stricker, Agreement between the pharmacy medication history and patient interview for cardiovascular drugs: the Rotterdam elderly study, British Journal of Clinical Pharmacology, 1998, 45, 6
  21. 21
    Nigel S.B. Rawson, Sheila Rutledge Harding, Edith Malcolm, Leah Lueck, Hospitalizations for Aplastic Anemia and Agranulocytosis in Saskatchewan, Journal of Clinical Epidemiology, 1998, 51, 12, 1343

    CrossRef

  22. 22
    Luis A. García Rodríguez, Susanne Pérez Gutthann, Use of the UK General Practice Research Database for pharmacoepidemiology, British Journal of Clinical Pharmacology, 1998, 45, 5
  23. 23
    Hong S. Lau, Anthonius de Boer, Karin S. Beuning, Arijan Porsius, Validation of pharmacy records in drug exposure assessment, Journal of Clinical Epidemiology, 1997, 50, 5, 619

    CrossRef

  24. 24
    Berthold Rzany, Maja Mockenhaupt, Susan Baur, Werner Schröder, Ulrich Stocker, Judit Mueller, Norbert Holländer, Rudolf Bruppacher, Erwin Schöpf, Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): Structure and results of a population-based registry, Journal of Clinical Epidemiology, 1996, 49, 7, 769

    CrossRef

  25. 25
    Judith Parsells Kelly, Ariane Auquier, Berthold Rzany, Luigi Naldi, Sylvie Bastuji-Garin, Osvaldo Correia, Samuel Shapiro, David W. Kaufman, An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods, Journal of Clinical Epidemiology, 1995, 48, 9, 1099

    CrossRef

  26. 26
    Berthold Rzany, Maja Mockenhaupt, Norbert Holländer, Ulrich Stocker, Judit Mueller, Susan Baur, Erwin Schöpf, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): Evaluation for drug risk based on sale numbers in defined daily doses (DDD). Example of the H2-antagonists, Pharmacoepidemiology and Drug Safety, 1995, 4, 4
  27. 27
    Suzanne L. West, Brian L. Strom, Bruce Freundlich, Esther Normand, Gary Koch, David A. Savitz, Completeness of prescription recording in outpatient medical records from a health maintenance organization, Journal of Clinical Epidemiology, 1994, 47, 2, 165

    CrossRef

  28. 28
    U. Bergman, B-E. Wiholm, F. Rosa, C. Baum, G.A. Faich, B-E. Wiholm, Effects of exposure to benzodiazepine during fetal life, The Lancet, 1992, 340, 8821, 694

    CrossRef

  29. 29
    Clement J. McDonald, Siu L. Hui, The analysis of humongous databases: Problems and promises, Statistics in Medicine, 1991, 10, 4
  30. 30
    B. L. Strom, Pharmacoepidemiology, Study Designs, Encyclopedia of Biostatistics,
  31. 31
    David Lee, Ulf Bergman, Studies of Drug Utilization,
  32. 32
    Gerald J. Dal Pan, Peter Arlett, The Role of Pharmacoepidemiology in Regulatory Agencies,
  33. 33
    Suzanne L. West, Mary Elizabeth Ritchey, Charles Poole, Validity of Pharmacoepidemiologic Drug and Diagnosis Data,